Pathology, research and practice · 2023
Fast and reliable Sanger POLE sequencing protocol in FFPE tissues of endometrial cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Laczmanska Izabela, Michalowska Dagmara, Jedryka Marcin, Blomka Dorota, Semeniuk Mariola, Czykalko Ewelina, Abrahamowska Mariola, Mlynarczykowska Paulina, Chrusciel Agnieszka, Pawlak Ireneusz, Maciejczyk Adam
Аннотация
BACKGROUND: The new classification of endometrial carcinoma (EC) requires molecular interpretation of somatic polymerase epsilon (POLE) exonuclease domain mutations. The identification of pathogenic mutations within the POLE gene defines the important subtype of ultramutated tumours ("POLE-ultramutated") with specified prognostic and predictive utility. POLE somatic mutations are present in 7-12% of ECs, usually high-grade tumours with aggressive appearance. Molecular analysis of the POLE gene can be performed using a qPCR test, the Sanger sequencing method, a next generation sequencing (NGS) panel test and also in situ hybridisation (IHC) assay. We describe our current approach of identification of POLE mutations using Sanger sequencing technology, which is still the most robust, accurate and fast technique to sequence DNA.
MATERIALS AND METHODS: We present a reliable protocol for Sanger sequencing of the entire sequence coding exonuclease domain of POLE - exons 9, 10, 11, 12, 13 and 14 (codons 268-491) with 5-10 nucleotides in exon/intron boundaries (reference sequences: NM_006231.4, NP_006222.2).
RESULT: The protocol has been optimized for formalin-fixed, paraffin-embedded (FFPE) EC tissues.
CONCLUSION: The method developed in our laboratory allows better diagnosis of patients with EC according to current standards.
MATERIALS AND METHODS: We present a reliable protocol for Sanger sequencing of the entire sequence coding exonuclease domain of POLE - exons 9, 10, 11, 12, 13 and 14 (codons 268-491) with 5-10 nucleotides in exon/intron boundaries (reference sequences: NM_006231.4, NP_006222.2).
RESULT: The protocol has been optimized for formalin-fixed, paraffin-embedded (FFPE) EC tissues.
CONCLUSION: The method developed in our laboratory allows better diagnosis of patients with EC according to current standards.